Axiron is a type of testosterone treatment that comes in the form of an underarm topical solution. The medication works by replacing the testosterone that is naturally produced by the male body. A natural part of male aging is a decline in testosterone production, and the associated effects of low testosterone (male hypogonadism) may prompt some men to use low T treatments such as Axiron.
Manufactured by Eli Lilly and Company, Axiron was first approved by the U.S. Food and Drug Administration (FDA) in 2010. The topical solution is applied to clean, dry skin on the underarms.
Along with other low T treatments, Axiron has been linked to an increased risk of stroke, heart attack or death. Studies have shown that men with heart problems were more likely to suffer a stroke, heart attack or death compared to healthy men who were not taking low T treatments such as Axiron.
If you or someone you love has been harmed by Axrion, you may have legal rights. Our legal advocates are available to help.make an appointment
If you or a loved one is currently taking Axrion, talk to a doctor before discontinuing use. Always discuss the benefits and risks of discontinuing use of any medication with a physician.
"I am very pleased and had a wonderful experience with the firm. Would definitely use their services again."
"I appreciate all that the Simmons firm has done for me. I’m thrilled with the result they got for me and want to say thanks to everyone there."
"I lost my wife to a heart attack caused by a dangerous drug. While nothing I do will ever bring her back, the Simmons firm helped ensure that other people won’t have to suffer the same loss as me. That product is no longer on the market and the company responsible for selling it to my wife paid a heavy financial price for hurting people like her."
"My mom had a catastrophic stroke as a result of taking a weight-loss product. The Simmons firm fought tirelessly to get her the best result possible. Thanks to them we can afford to get her the medical and therapeutic care she needs."